Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo-controlled study. METHODS: Patients with curative therapy were assigned to one of the following regimens: peretinoin 600, 300 mg/day, or placebo for up to 96 weeks. The primary outcome was recurrence-free survival (RFS). RESULTS: Of the 401 patients initially enrolled, 377 patients were analyzed for efficacy. The RFS rates in the 600-mg group, the 300-mg group, and the placebo group were 71.9, 63.6, and 66.0 % at 1 year, and 43.7, 24.9, and 29.3 % at 3 years, respectively. The primary comparison of peretinoin (300 and 600-mg) with placebo was not significant (P = 0.434). The dose-response relationship based on the hypothesis that "efficacy begins to increase at 600 mg/day" was significant (P = 0.023, multiplicity-adjusted P = 0.048). The hazard ratios for RFS in the 600-mg group vs. the placebo group were 0.73 [95 % confidence interval (CI) 0.51-1.03] for the entire study period and 0.27 (95 % CI 0.07-0.96) after 2 years of the randomization. Common adverse events included ascites, increased blood pressure, headache, presence of urine albumin, and increased transaminases. CONCLUSIONS: Although the superiority of peretinoin to placebo could not be validated, 600 mg/day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-HCC, particularly after 2 years. The efficacy and safety of peretinoin 600 mg/day should continue to be evaluated in further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805 · cited 1×
“Curative resection or ablation is indicated for early HCC [5–7].”
BackgroundLlovet, J. M., Burroughs, A., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,608
The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002
Armstrong, G. L., Wasley, A., Simard, E. P., McQuillan, G. M., Kuhnert, W. L., & Alter, M. J. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-10-200605160-00004 · Cited by 1,955
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Altekruse, S. F., McGlynn, K. A., & Reichman, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7753 · Cited by 1,694
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653 · cited 1×
“The guidelines for clinical studies of HCC recommend inclusion of patients with Child-Pugh A in clinical trials because death from cirrhosis in patients with Child-Pugh B or C could mask the efficacy of treatment [28].”
BackgroundImamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589 · cited 3×
“However, multicentric de novo carcinogenesis is the common cause of recurrence after 2 years [11, 12].”
BackgroundSelf-citation[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943 · cited 1×
“The incidence of HCC has been rising due to an increase in hepatitis-C virus infections [2–4].”
Background
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
“regulatory agreement, incorporated a composite endpoint of recurrence-free survival, where around 90% of events were recurrences.(394,628) Regulatory agencies endorse this composite”
BackgroundAASLD guidelines for the treatment of hepatocellular carcinoma
Heimbach, J. K., Kulik, L. M., Finn, R. S., Sirlin, C. B., Abecassis, M. M., Roberts, L. R., Zhu, A. X., Murad, M. H., & Marrero, J. A. (2018) · Hepatology · doi:10.1002/hep.29086 · Cited by 4,070
“Early studies with the adjuvant use of acyclic retinoids were promising,((50)) with a decrease in the development of secondary tumors, but larger studies did not confirm a benefit.((51)) The lack of proven active agents in advanced disease has hampered the development of agents targeting early-stage disease.”
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
“However, in a large-scale RCT, the superiority of acyclic retinoid over placebo could not be validated, 600 mg per day was shown to be the optimal dose, and treatment may possibly reduce the recurrence of HCV-related HCC, particularly after 2 years [211].”
BackgroundSelf-citationHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Bruix, J., Takayama, T., Mazzaferro, V., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R. T., Han, K.-H., Tak, W. Y., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00198-9 · Cited by 1,120
Self-citationEASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Fujiwara, N., Friedman, S. L., Goossens, N., & Hoshida, Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.016 · Cited by 659
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
“A study demonstrating benefit of retinoid administration(72) was not confirmed in a subsequent multicenter trial(73) and small studies suggesting benefit from adoptive immunotherapy(74) and I-131 lipiodol embolization of the liver remnant,(75) the results of which have not been duplicated.”
BackgroundSelf-citationAdjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
“For instance, adjuvant administration of retinoids 85 , vitamin K2 (ref.”
Self-citationHaber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma
Hoshida, Y., Fuchs, B. C., Bardeesy, N., Baumert, T. F., & Chung, R. T. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.010 · Cited by 230
“An acyclic retinoid, peretinoin, was tested in a large-scale phase 3 trial, enrolling HCV-related cirrhosis patients, which showed modest HCC preventive effect [132].”
Hepatitis C virus-induced hepatocellular carcinoma
Goossens, N., & Hoshida, Y. (2015) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2015.21.2.105 · Cited by 172
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Kudo, M. (2018) · Cancers · doi:10.3390/cancers10110412 · Cited by 172
“Three phase III trials, one comparing vitamin K2 with placebo as adjuvant chemotherapy after radiofrequency ablation or resection [6], one comparing sorafenib with placebo (STORM trial) [7], one comparing peretinoin with placebo (NIK333 trial) [8], and one comparing ablation plus lyso-thermosensitive liposomal doxorub…”
BackgroundMethodSelf-citationRetinoids and rexinoids in cancer prevention: from laboratory to clinic
Uray, I. P., Dmitrovsky, E., & Brown, P. H. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.002 · Cited by 162
“Based on the results of a phase I pharmacokinetic study 300–600 mg/day were considered safe and used in a subsequent phase II/III randomized, double-blind, placebo-controlled study of peretinoin in patients with hepatitis C-related HCC, to determine benefits in recurrence-free survival (RFS) as a primary outcome [148].”
MethodTargeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Kudo, M. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i7.789 · Cited by 150
Self-citationSystemic Therapy for Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2017) · Oncology · doi:10.1159/000481244 · Cited by 134
Self-citationWen, T., Chen, J., Facciorusso, A., Donadon, M., Han, H., Mao, Y., Dai, C., Cheng, S., Zhang, B., Peng, B., et al. (2018) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.08.01 · Cited by 116
“TACE (34,63,66-69), antiviral therapy (70-72), immunomodulation therapy, such as thymosin α1 (73-75) or interferon (76-79), sorafenib (80-82) and vitamin K2 (83-87), could be considered for patients who are at risk of recurrence.”
BackgroundQin, X., Suzuki, H., Honda, M., Okada, H., Kaneko, S., Inoue, I., Ebisui, E., Hashimoto, K., Carninci, P., Kanki, K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802279115 · Cited by 115
Self-citationRecent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update
Kudo, M. (2020) · Liver Cancer · doi:10.1159/000511001 · Cited by 113
Self-citationImmuno-Oncology in Hepatocellular Carcinoma: 2017 Update
Kudo, M. (2017) · Oncology · doi:10.1159/000481245 · Cited by 103
Self-citationKing, L. Y., Canasto‐Chibuque, C., Johnson, K. B., Yip, S. H., Chen, X., Kojima, K., Deshmukh, M., Venkatesh, A., Tan, P. S., Sun, X., et al. (2014) · Gut · doi:10.1136/gutjnl-2014-307862 · Cited by 85
Self-citationCombination Cancer Immunotherapy in Hepatocellular Carcinoma
Kudo, M. (2018) · Liver Cancer · doi:10.1159/000486487 · Cited by 81
Self-citationMolecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000452138 · Cited by 80
Self-citationRecent advances in medical management of hepatocellular carcinoma
Ikeda, K. (2018) · Hepatology Research · doi:10.1111/hepr.13259 · Cited by 75
Self-citationImmuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000501501 · Cited by 71
Self-citationZhu, X., Li, K., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.02.002 · Cited by 68
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence
Lu, L., Poon, R. T. P., & Cheng, A. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394141 · Cited by 63
Wu, J., Chan, Y.-T., Lu, Y., Wang, N., & Feng, Y. (2023) · Medicinal Research Reviews · doi:10.1002/med.21967 · Cited by 58
“Significantly, 600mg/day treatment tretinoin, an acyclic retinoid, showed significant efficacy in reducing the recurrence of HCC, particularly 2 years after curative treatment in phase III clinical trial.(196) As pointed before, based on the cut‐off of 2 years, HCC recurrence is divided”
MethodChemopreventive Potential of Green Tea Catechins in Hepatocellular Carcinoma
Shimizu, M., Shirakami, Y., Sakai, H., Kubota, M., Kochi, T., Ideta, T., Miyazaki, T., & Moriwaki, H. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16036124 · Cited by 62
“Administration of acyclic retinoid, which can suppress the post-therapeutic recurrence of HCC and improve the survival rate of patients [41,42], also inhibited DEN-induced liver tumorigenesis in db/db mice, and this was associated with improved liver steatosis and insulin sensitivity [43].”
BackgroundSelf-citationA Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma
Kudo, M. (2020) · Liver Cancer · doi:10.1159/000507934 · Cited by 48
Self-citationDedifferentiation of hepatocellular carcinoma: molecular mechanisms and therapeutic implications.
Chao, J., Zhao, S., & Sun, H. (2020) · PubMed Central · Cited by 52
The Peretinoin Study Group, Okita, K., Izumi, N., Ikeda, K., Osaki, Y., Numata, K., Ikeda, M., Kokudo, N., Imanaka, K., Nishiguchi, S., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-0996-1 · Cited by 40
“89) [18], and the hazard ratio of overall survival for peretinoin 600 mg/day and placebo was 0.”
BackgroundSelf-citationNew treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Kudo, M. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02166-0 · Cited by 40
Self-citationFunaki, M., Kitabayashi, J., Shimakami, T., Nagata, N., Sakai, Y., Takegoshi, K., Okada, H., Murai, K., Shirasaki, T., Oyama, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17285-2 · Cited by 37
Self-citationRetinoid roles in blocking hepatocellular carcinoma.
Shirakami, Y., Sakai, H., & Shimizu, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2015.05.01 · Cited by 47
“(45) have reported that ACR administration caused several adverse reactions, including onychoclasis, headache, anemia, renal impairment, and edema.”
BackgroundInfluentialAdjuvant Immunotherapy after Curative Treatment for Hepatocellular Carcinoma
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000518584 · Cited by 33
Self-citationSinopoli, A., Caminada, S., Isonne, C., Santoro, M. M., & Baccolini, V. (2022) · Nutrients · doi:10.3390/nu14194081 · Cited by 35
“The risk of bias was low for the Japanese study [45], while the other trials were at high risk of bias [46,48] or had some concerns [47] (Supplementary Table S2).”
BackgroundMethodResultInfluentialTakami, T., Yamasaki, T., Saeki, I., Matsumoto, T., Suehiro, Y., & Sakaida, I. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7252 · Cited by 32
Retinoids in cancer chemoprevention and therapy: Meta-analysis of randomized controlled trials
Chen, S., Hu, Q., Tao, X., Xia, J., Wu, T., Cheng, B., & Wang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1065320 · Cited by 30
“As for event-free survival, three studies (Kohler et al., 2000; Shinagawa et al., 2014; Okita et al., 2015b) with 556 patients evaluated the relationship between retinoids and event-free survival.”
BackgroundSurgical outcomes of hepatocellular carcinoma with biliary tumor thrombus: a systematic review
Qiao, W., Yu, F., Wu, L., Li, B., & Zhou, Y. (2016) · BMC Gastroenterology · doi:10.1186/s12876-016-0427-2 · Cited by 30
Changes in therapeutic options for hepatocellular carcinoma in Asia
Ogasawara, S., Koroki, K., Kanzaki, H., Kobayashi, K., Kiyono, S., Nakamura, M., Kanogawa, N., Saito, T., Kondo, T., Nakagawa, R., et al. (2021) · Liver International · doi:10.1111/liv.15101 · Cited by 28
Shidoji, Y., & Tabata, Y. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m090548 · Cited by 26
“(7) have been essentially confirmed by another multicenter clinical trial with larger size cohorts and different doses of acyclic retinoid (8, 9).”
BackgroundTabata, Y., & Shidoji, Y. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000610 · Cited by 26
Generic chemoprevention of hepatocellular carcinoma
Divakar, S. K. A., & Hoshida, Y. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13971 · Cited by 28
Su, Y., Li, C.-C., Lin, Y., & Hsu, C. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1730949 · Cited by 24
Tabata, Y., Omori, M., & Shidoji, Y. (2021) · Metabolites · doi:10.3390/metabo11090634 · Cited by 19
“Indeed, the 4,5-didehydro derivative of GGA potentially prevented second primary hepatoma in placebo-controlled randomized phase II/III clinical trials [3,4].”
BackgroundImpact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
Seidensticker, M., Öcal, O., Schütte, K., Malfertheiner, P., Berg, T., Loewe, C., Klümpen, H., van Delden, O. M., Ümütlü, M. R., Khaled, N. B., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100699 · Cited by 18
Iwao, C., & Shidoji, Y. (2015) · Biomedical Research · doi:10.2220/biomedres.36.371 · Cited by 19
Hepatocellular carcinoma systemic treatment update: From early to advanced stage
Teng, W., Wu, T.-C., & Lin, S. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100815 · Cited by 17
“For example, the adjuvant use of retinoids [31], vitamin K2 [32], or interferon-α [33] and 131 I-lipiodol embolization [34] failed to show significant efficacy.”
Sakai, H., Shirakami, Y., & Shimizu, M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i1.394 · Cited by 15
Acyclic retinoid induces differentiation and apoptosis of murine hepatic stem cells
Guan, H.-B., Nie, Y., Zheng, Y., Takiguchi, K., Yu, H., Zhang, R., Li, B., Tsuchida, T., & Taniguchi, H. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0046-9 · Cited by 14
“Clinical studies have found that ACR can significantly reduce the incidence of post-therapeutic hepatocellular carcinoma (HCC) recurrence and improve the survival rate of HCC patients [11-14].”
BackgroundPeretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma
Woo, H. Y., Yoo, S. Y., & Heo, J. (2021) · Molecules · doi:10.3390/molecules26020295 · Cited by 12
“These results suggested that twice daily administration of 600 mg/day peretinoin was clinically effective in preventing the recurrence of HCC [42].”
BackgroundMethodInfluentialShidoji, Y. (2024) · Cells · doi:10.3390/cells13100809 · Cited by 11
“Subsequently, larger-scale clinical trials confirmed the hepatocellular carcinoma recurrence inhibitory effect of peretinoin [7,8].”
BackgroundAdjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
Kudo, M. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-203 · Cited by 10
“However, although numerous clinical trials have evaluated adjuvant therapies to suppress recurrence, all have concluded with negative results (4-6).”
Self-citationYabuta, S., & Shidoji, Y. (2019) · Hepatic Oncology · doi:10.2217/hep-2018-0008 · Cited by 9
Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need
Minami, Y., & Kudo, M. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.04.05 · Cited by 9
“However, studies of adjuvant treatment using acyclic retinoid or vitamin K2 failed to show their efficacy for the prevention of recurrence after curative therapy (9,10).”
BackgroundSelf-citationChan, J. Y., Lim, A. H., Boot, A., Lee, E. H., Ng, C. C. Y., Lee, J. Y., Rajasegaran, V., Liu, W., Goh, S. E., Hong, J. H., et al. (2020) · Liver Cancer International · doi:10.1002/lci2.14 · Cited by 8
Qin, X., Shirakami, Y., Honda, M., Yeh, S., Numata, K., Lai, Y., Li, C., Wei, F., Xu, Y., Imai, K., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34893 · Cited by 8
“19 As HCC recurrence involves metastatic and de novo mechanisms, with early recurrence resulting from intrahepatic metastasis and late recurrence from de novo tumorigenesis, 34 ACR may be more effective in preventing the latter recurrence of HCC by selectively targeting MYCN-expressing liver cancer…”
BackgroundSelf-citationDelivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma
Stefanini, B., Manfredi, G. F., D’Alessio, A., Fulgenzi, C. A. M., Awosika, N. O., Celsa, C., Pirisi, M., Rigamonti, C., Burlone, M. E., Vincenzi, F., et al. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2419519 · Cited by 9
“Neither of them, unfortunately, succeeded in demonstrating a benefit in RFS in phase III trials [29,31].”
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
Kudo, M. (2023) · Liver Cancer · doi:10.1159/000531225 · Cited by 8
Self-citationMolecular Targeted Therapy for Hepatocellular Carcinoma: Where Are We Now?
Obi, S., Sato, S., Kawai, T., Ichikawa, S., Ichikawa, T., Motosugi, U., Sano, K., Morisaka, H., Enomoto, N., Matsuda, M., et al. (2015) · Liver Cancer · doi:10.1159/000367753 · Cited by 7
Prevention Strategies for Hepatocellular Carcinoma
Erstad, D. J., Razavi, A. A., Shen, L., Tanabe, K. K., & Fuchs, B. C. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8_13 · Cited by 7
Nishimura, N., Kaji, K., Kitade, M., Aihara, Y., Sato, S., Seki, K., Sawada, Y., Takaya, H., Okura, Y., Kawaratani, H., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-5099-6 · Cited by 7
Zhang, J., Li, H., Dong, J., Zhang, N., Liu, Y., Luo, X., Chen, J., Wang, J., & Wang, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.620594 · Cited by 7
“15 recurrence in HCC patients, and as well as to improved outcomes [39, 40].”
What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma?
Kokudo, T., & Kokudo, N. (2020) · Global Health & Medicine · doi:10.35772/ghm.2020.01086 · Cited by 5
Self-citationOmori, M., Shidoji, Y., & Moriwaki, H. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3040034 · Cited by 5
“In a randomized clinical trial (RCT) of dGGA using a placebo, 600 mg of dGGA was orally administered daily per person for one year after curative therapy for hepatoma [5,14], and in a separate RCT dGGA, 600 mg, 300 mg, or placebo was orally administered daily per person for 96 weeks [15,16].”
MethodSelf-citationPeretinoin as an adjuvant therapy for hepatocellular carcinoma
Tan, C. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1238303 · Cited by 5
Oncogenic function and transcriptional dynamics of MYCN in liver tumorigenesis
Qin, X., Xu, Y., Mishra, H., Shirakami, Y., Yeh, S., Li, C., Numata, K., Suenaga, Y., Wei, F., Ando, R., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2521923123 · Cited by 4
“…trials have attempted to reduce the risk of recurrence through preventive strategies, including nutritional interventions, such as acyclic retinoid (3) and vitamin K (4), and trials on molecular targeted agents, such as the STORM trial with sorafenib (5), and adjuvant immunotherapy such as the…”
Self-citationKudo, M. (2024) · Liver Cancer · doi:10.1159/000542221 · Cited by 5
Self-citationOtsuka, K., Sasada, M., HIRANO, Y., NOHARA, Y., Iyoda, T., Higami, Y., Kodama, H., & Fukai, F. (2019) · Anticancer Research · doi:10.21873/anticanres.13494 · Cited by 4
Sakai, H., Shimizu, M., & Moriwaki, H. (2014) · Diseases · doi:10.3390/diseases2030226 · Cited by 5
“preserved liver function (Child-Pugh A) [81].”
Self-citationThe Potential of Stem Cells in Treating Breast Cancer
Yadav, D., Sharma, P. K., Mishra, P. S., & Malviya, R. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230428094056 · Cited by 3
Öcal, O., Schütte, K., Malfertheiner, P., Berg, T., Loewe, C., Klümpen, H., Zech, C. J., van Delden, O. M., Ümütlü, M. R., Deniz, S., et al. (2023) · European Journal of Radiology · doi:10.1016/j.ejrad.2023.111120 · Cited by 3
Wang, Y., Xu, J., Zhang, L., Tong, J., Liu, C., Li, W., Zhang, Q., Cao, D., Chen, X., Zuo, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002417 · Cited by 3
Asada, A., Shioya, M., Osaki, R., Nishimura, T., Takeuchi, T., Okumura, Y., & Andoh, A. (2014) · Biomedical Reports · doi:10.3892/br.2014.406 · Cited by 3
“Successful treatment, termed sustained virological response (SVR), is defined as undetectable HCV RNA 6 months after cessation of treatment (10-12).”
Non-surgical Treatment Options in Managing Recurrent Hepatocellular Carcinoma
Abdelhamed, W., & El‐Kassas, M. (2023) · Gene Expression · doi:10.14218/ge.2023.00010 · Cited by 2
Systemic therapy of hepatocellular carcinoma: reality and prospects
Breder, V. V., Натрусова, М. В., & Анатольевна, Д. И. (2020) · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · doi:10.16931/1995-5464.2020227-38 · Cited by 2
Shidoji, Y., & Iwao, C. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101176 · Cited by 2
“Indeed, peretinoin was shown to have the potential to prevent SPH in randomized, placebo-controlled phase II/III clinical trials [6,7].”
BackgroundHow do we conquer the recurrence of HCC?
Nouso, K. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-014-1003-6 · Cited by 2
Li, H., Zhang, J., Dong, J., Zheng, X., Lei, C., Wang, H., Zhang, N., Liu, Y., Luo, X., Chen, J., et al. (2020) · doi:10.21203/rs.2.23077/v1 · Cited by 2
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment
Yau, J., Chan, L. L., & Chan, S. L. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2578079 · Cited by 1
“Other agents including retinoid [107], vitamin K2 [108], and HAic [109] all failed to show benefit as adjuvant treatment in Hcc. iMBrave050 is the first trial to report adjuvant immunotherapy outcomes in Hcc. in this international randomized phase iii study, 668 patients were randomly assigned…”
Olesinski, J., Mithieux, F., Guillaud, O., Hilleret, M., Lombard‐Bohas, C., Henry, L., Boillot, O., Walter, T., Partensky, C., Paliard, P., et al. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1165-4 · Cited by 1
“However, a recent randomized controlled trial assessing another retinoid in HCVrelated HCC showed no significant improvement in recurrence-free survival with a significant rise of adverse effects [24].”
BackgroundAbdelmaksoud, E. M., Salem, A. M. H., Maher, A. M., & Hegazy, M. G. A. (2020) · Tropical biomedicine · doi:10.47665/tb.37.4.1083 · Cited by 1
Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East
Al‐Busafi, S. A., & Al-Naamani, K. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78737-0_17
Wu, J., Zhang, C., Chan, Y.-T., Lu, Y., Tan, H., Feng, Y., & Wang, N. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4153442
Tabata, Y., Omori, M., & Shidoji, Y. (2022) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pab.1.22.9
Editorial: Cancer and nutrients: new chemicals, signals, and biomarker-based therapy
Qin, X., Mendoza-Parra, M. A., & Shirakami, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1190065
New insights into the role of CYP26 in retinoic acid clearance
Innes, J., Whiting, A., & McCaffery, P. J. A. (2026) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2026.2664480
“…prevention; peretinoin (an acyclic retinoid) has been tested in randomized trials for secondary prevention of hepatocellular carcinoma recurrence after curative therapy, showing continued interest in therapeutic modulation of hepatic retinoic signaling in chronic liver disease settings [73,74].”
Okada, H., Nio, K., Ohno, N., Masuo, Y., Hirokawa, T., Shimakami, T., Miyati, T., Takamura, H., Ohta, T., Kitao, A., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201246
“13 As the name peretinoin indicates, PA was initially considered an acyclic retinoid owing to its binding to retinoid X receptor alpha (RXR α ), 14 and evidence suggests that aberrant retinoic acid (RA) signaling may contribute to oncogenesis.”
Self-citationНОВЫЕ ВОЗМОЖНОСТИ ИММУНОТЕРАПИИ В ЛЕЧЕНИИ ГЕПАТОЦЕЛЛЮЛЯРНОЙ КАРЦИНОМЫ. ОБЗОР ЛИТЕРАТУРЫ
Зульфатовна, И. А. (2025) · Поволжский онкологический вестник · Cited by 1
Okura, K., Yoh, T., Yao, Z., Nakanuma, S., Nakamura, I., Hori, Y., Nakamura, K., Ishii, T., Hirono, S., Yagi, S., et al. (2026) · Liver Cancer · doi:10.1159/lic/admag008
Metadata
- Authors
- Peretinoin Study Group, Okita, K., Izumi, N., Matsui, O., Tanaka, K., Kaneko, S., Moriwaki, H., Ikeda, K., Osaki, Y., Numata, K., Nakachi, K., Kokudo, N., Imanaka, K., Nishiguchi, S., Okusaka, T., Nishigaki, Y., Shiomi, S., Kudo, M., Ido, K., Karino, Y., Hayashi, N., Ohashi, Y., Makuuchi, M., & Kumada, H.
- Affiliations
- Musashino Red Cross Hospital (JP)
- Kanazawa University Hospital (JP)
- Yokohama City University Medical Center (JP)
- Gifu University Hospital (JP)
- Osaka Red Cross Hospital (JP)
- University of Tokyo Hospital (JP)
- Osaka International Cancer Institute (JP)
- Hyogo Medical University Hospital (JP)
- Gifu Municipal Hospital (JP)
- Kindai University Hospital (JP)
- Sapporo Kosei General Hospital (JP)
- Kansai Rosai Hospital (JP)
- Japanese Red Cross Medical Center (JP)
- Japanese Red Cross Society, Japan (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Okita, Kiwamu
- ORCID
- Venue
- Journal of Gastroenterology
- Published
- 2014-04-13
- Volume
- 50
- Issue
- 2
- Pages
- 191-202
- ISSN
- 0944-1174 (ISSN-L)
- 1435-5922
- PMC
- PMC4318984
- OpenAlex
- W2022144305
- Cited by
- 90
- References
- 34
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 9 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 4 · 2015: 9 · 2014: 7
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Taiho Pharmaceutical
- Nihon Medi-Physics
- Kowa Company
- Boehringer Ingelheim Japan
- Nippon Shinyaku
- Dainippon Sumitomo Pharma
- Eisai
- Kyowa Hakko Kirin
- Astellas Pharma
- Otsuka Pharmaceutical
- Ajinomoto Pharmaceuticals
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- Chugai Pharmaceutical
- Japan Society for the Promotion of Science (221S0001)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- recurrent hepatocellular carcinoma, recurrence-free survival, adjuvant therapy, dose-response relationship, curative treatment, hepatoprotection, adverse events
- MeSH terms
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retinoids, Anticarcinogenic Agents, Treatment Outcome, Disease-Free Survival, Hepatitis C, Chronic, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.